Gisadenafil besylate

Key Product Details

Product Description

Gisadenafil besylate is a potent PDE5 inhibitor (IC₅₀ = 1.23 nM). Shows >100-fold selectivity for PDE5 over PDE6. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for Gisadenafil besylate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Gisadenafil besylate

The following data is based on the product molecular weight 677.79.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.48 mL	7.38 mL	14.75 mL
5 mM	0.30 mL	1.48 mL	2.95 mL
10 mM	0.15 mL	0.74 mL	1.48 mL
50 mM	0.03 mL	0.15 mL	0.30 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Rawson The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg.Med.Chem. 2012 PMID:  22100260
• Hashim and Abrams Emerging drugs for the treatment of benign prostatic obstruction. Exp.Opin.Invest.Drugs 2010 PMID: 20446824

Product Documents for Gisadenafil besylate